China Cord Blood (CO) Reports In-Line Q4 EPS

China Cord Blood (NYSE: CO) reported Q4 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $24.3 million versus the consensus estimate of $25.87 million.

For earnings history and earnings-related data on China Cord Blood (CO) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c